论文部分内容阅读
目的 探讨WT1基因mRNA表达与恶性血液病的关系及意义。方法 应用逆转录 聚合酶链反应法 (RT PCR)测定 141例不同类型恶性血液病患者和 10名正常人外周血WT1基因的表达。结果 6 9 9%急性白血病 (AL)WT1表达阳性 ,其中急性髓系白血病 (AML) 6 5 2 % ,急性淋巴细胞白血病 (ALL) 77 8% ;40 0 %慢性粒细胞白血病 (CML)WT1表达阳性 ,其中 7例急变者全部为阳性 ;2例骨髓增生异常综合征 (MDS) RAEBTWT1表达阳性 ;非霍奇金氏淋巴瘤 (NHL)、多发性骨髓瘤 (MM )均为低表达 ;3例MDS RA ,10名正常人WT1表达阴性。结论 WT1基因在各类型白血病、MDS中均能表达 ,表达水平与体内白血病细胞的数量、病程进展等相关。可作为化疗和骨髓移植后微小残留病检测的敏感指标 ,也是研究白血病、MDS发病、发展和预测预后的手段
Objective To investigate the relationship between WT1 mRNA expression and hematological malignancy and its significance. Methods Reverse transcription polymerase chain reaction (RT PCR) was used to determine the expression of WT1 gene in peripheral blood of 141 patients with different types of hematological malignancies and 10 normal controls. Results Positive expression of WT1 was observed in 69% of acute leukemia (AL), of which acute myeloid leukemia (AML) was 625%, acute lymphoblastic leukemia (ALL) was 77%, and 400% of chronic myeloid leukemia (CML) WT1 was expressed. Positive, all 7 cases of rapid change were positive; 2 cases of myelodysplastic syndrome (MDS) RAEBTWT1 positive expression; non-Hodgkin’s lymphoma (NHL), multiple myeloma (MM) were low expression; 3 cases MDS RA, 10 normal WT1 expression was negative. Conclusion WT1 gene can express in all types of leukemia and MDS. The expression level of WT1 gene is related to the number of leukemic cells in vivo and the progression of the disease. It can be used as a sensitive indicator for the detection of minimal residual disease after chemotherapy and bone marrow transplantation. It is also a means to study the onset, development and prognosis of leukemia and MDS.